CopyMark Law Group
4.9/5
Drawing for ISONOVA

USPTO serial 98510322

ISONOVA

Reviewed by CopyMark Law Group

Reg. 7702936Status 700Registered
Filing date
Status date
Registration date
Feb 25, 2025
Examiner
RENNIE, GABRIELLE M
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ISONOVA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Lindsay B. Allen

Lindsay B. Allen Perkins Coie LLPP.O. Box 2608Seattle, WA 98111United States

Goods and services

ClassDescriptionStatusFirst use
009Downloadable software for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; downloadable computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for predicting protein structure, discovering drugs, designing drug candidates, biologic product development, and pharmaceutical product development; downloadable computer software, computer programs and computer software algorithms for manipulating received or inputted data generated in a virtual space in connection with artificial intelligence methods, machine learning methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, and predictive assistance technologies, for protein structure prediction, l drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; downloadable computer software for conducting therapeutic product research and development; downloadable computer software for discovering, optimizing and developing drugs; downloadable computer software for designing and developing drug candidatesACTIVE—
042Software as a service (SAAS) services featuring software for protein structure prediction, drug discovery, drug candidate design, biological product development, and pharmaceutical product development; software as a service (SAAS) services featuring software using artificial intelligence, machine learning, deep learning, or reinforcement learning for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; platform as a service (PaaS) services featuring software for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; platform as a service (PaaS) services featuring software using artificial intelligence, machine learning, deep learning, and reinforcement learning for protein structure prediction, drug discovery, development of biologic materials, development of biologic products, and pharmaceutical product development; advanced product research, design and development in the field of artificial intelligence for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; research and development in the fields of artificial intelligence, machine learning, deep learning, and reinforcement learning technologies for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; technology research in the field of artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; providing online, non-downloadable computer software platforms for protein structure prediction, drug discovery, drug candidate design, biologic material development, , and pharmaceutical product development; providing online, non-downloadable computer software platforms using artificial intelligence, machine learning, deep learning, or reinforcement learning for protein structure prediction, drug discovery, drug candidate design, biological produce development, and pharmaceutical product development; testing of computing methods, computer software algorithms, computer software, and computer hardware for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; scientific, pharmaceutical, biotech, medical, and artificial intelligence research; scientific research in the field of computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for medical research, pharmaceutical research, biotech research, protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; product research and development; medical, pharmaceutical, biotech, and scientific research in the field of protein structure prediction, drug discovery, drug candidate design, biologic product development, pharmaceutical product development, and computational biology; scientific and technological services, namely, scientific research in the fields of analytics and data mining, data analysis, data transformation, data visualization, statistical analysis, artificial intelligence, machine learning, virtual reality, science, chemistry, medicinal chemistry, physics, biology, and digital biology, all for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer aided data analysis for scientific research purposes in the fields of artificial intelligence, machine learning, deep learning, reinforcement learning, building neural networks, data tree search, high performance computing, distributed computing, cloud computing, analytics and data mining, virtual reality, augmented reality, chemistry, medicinal chemistry, physics, biology, and digital biology, all for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer modelling services; technical or scientific services for the analysis of compositions of matter; technical consulting in the field of pharmaceutical studies; drug discovery, drug design, optimization and development services; research and development of therapeutic products; drug discovery, optimization and development services; medical and scientific services in the field of pharmaceuticals, namely, therapeutic and diagnostic candidate design servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 25, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Feb 25, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 7, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 7, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 1, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 14, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 14, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Dec 14, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 14, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 14, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 12, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 12, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 12, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 4, 2024DOCKASSIGNED TO EXAMINER—
Oct 7, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 19, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance